Novonesis: The enzyme champion that no one can copy

5-year stock timeline

Key Points

From recommendation (January 4, 2026)

• Market leader with almost 50% share in the specialty enzyme segment - decades of research and thousands of patented enzymes create an almost uncopyable competitive advantage
• Merger with Chr. Hansen successfully completed, sales growth forecast for 2025 raised to 7-8% organically
• Enzymes de facto indispensable in food, detergents and biofuels - chemical alternatives more expensive, more harmful to the environment and problematic from a regulatory perspective
• P/E ratio 15.5 with structural growth due to decarbonization pressure and expansion in emerging markets
• New Quara LowP product line addresses growing market for sustainable aviation fuel

Investment Thesis

From recommendation (January 4, 2026)

Novonesis unites according to the Chr. Hansen merger offers a unique combination of technological dominance, operational scaling and structural tailwind. The company controls a market in which enzymes are not only efficient, but increasingly without alternative - be it in food processing, biofuels or low-temperature detergents. Entering this market requires decades of research, extensive master collections, regulatory approvals and deep customer relationships - hurdles that remain virtually insurmountable. At the same time, global decarbonization pressure is structurally driving demand for biological process solutions, while the merger is showing initial synergies and strategically expanding the portfolio. With a P/E ratio of 15.5, an increased growth forecast and expansion potential in emerging markets, the share offers solid fundamental data with limited disruption risk until at least 2035.

Key risks and downside factors

Novozymes (NSIS-B.CO) manufactures industrial enzymes and microbial technologies for food and beverage, agriculture, household care, and technical applications. The competitive landscape divides between large diversified chemistry and nutrition companies with enzyme divisions—DSM-Firmenich, IFF/DuPont, BASF, Corteva among them—and smaller specialist enzyme makers like AB Enzymes and Chr. Hansen. The business faces several material headwinds. Synthetic biology platforms pose innovation risk to its core enzyme technology. Large chemical integrators apply persistent pricing and margin pressure. Agricultural and food biologicals encounter regulatory approval friction. Customer concentration and cyclical demand in its end markets create earnings volatility that compounds with economic cycles.

• Rapid advances in synthetic biology, cell engineering, and platform biotech—including design-foundries—could compress product lifecycles and erode Novozymes' historical R&D advantage.
• Large, diversified chemical and ingredient companies—BASF, DSM-Firmenich, IFF/DuPont—leverage scale and integrated product portfolios to capture contracts, creating competitive pressure that compresses margins for smaller players [8], [3].
• Regulatory and approval risk presents a material constraint for biologicals intended for food, feed, and agricultural use. Delays in the approval process or shifts toward stricter requirements can meaningfully restrict market access or elevate compliance costs in ways that affect unit economics [8], [3].
• End-market and customer concentration risk: the company depends on cyclical customers in detergents, agriculture, and food processing. Loss of any large customer could materially reduce revenues.

Competitive landscape

Novozymes (NSIS-B.CO) supplies industrial enzymes, microbial solutions and biotechnological services to food, agriculture, household care, bioenergy and industrial customers globally. The company faces competition from three distinct angles: diversified specialty-ingredients and life-sciences groups that bundle enzymes and cultures with broader formulation, flavor or crop inputs; focused enzyme specialists; and synthetic or chemical incumbents competing primarily on price and scale. The business carries meaningful risks around product displacement from faster R&D platforms and synthetic chemistry alternatives, exposure to raw-material and supply-chain cost volatility, the need for regulatory approvals and biosafety compliance across multiple jurisdictions, and customer concentration combined with pricing pressure in large industrial contracts.

Catalysts

From recommendation (January 4, 2026)

• Further synergy effects from Chr. Hansen merger could noticeably improve margins from 2026
• Regulatory tightening for decarbonization structurally driving demand for enzyme-based solutions
• Breakthroughs in sustainable aviation fuels with Quara LowP could open up new growth segment
• Successful expansion in emerging markets with rising demand for food and detergent enzymes

Analysis

From recommendation (January 4, 2026)

Performance Figures of Novonesis (Novozymes) A/S

in DKK

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

Frequently Asked Questions

From recommendation (January 4, 2026)

Key Metrics

From recommendation (January 4, 2026)

Valuation Metrics

Profitability Metrics

Growth Metrics

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.